Company
Headquarters: Belo Horizonte, MG, Brazil
Employees: 7,100
CEO: Mr. Roberto Santoro Meirelles
R$2.57 Billion
BRL as of April 1, 2023
US$536.2 Million
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $204.45 B |
| Danaher | $177.21 B |
| Siemens Healthineers AG | $63.84 B |
| DexCom, Inc. | $45.21 B |
| Lonza Group Ltd | $39.85 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Instituto Hermes Pardini S.A., together with its subsidiaries, provides medical, dental, laboratory research, clinical analysis, and supplementary diagnostic and therapeutic services in Brazil. It offers clinical analysis tests, diagnostic imaging, vaccines, check-ups, and other diagnostic services through 124 centers in the states of Minas Gerais, Goiás, São Paulo, and Rio de Janeiro. The company also provides lab-to-lab services, such as specialized tests for other laboratories, as well as consulting, training, and support services for its customers. It primarily operates through eight brands, which include Hermes Pardini, Progenética, Diagnóstika, Biocod, DLE, Labfar, Toxicologia Pardini, and Solução. The company serves hospitals, clinics, laboratories, and other companies in the health care sector. Instituto Hermes Pardini S.A. was founded in 1959 and is headquartered in Belo Horizonte, Brazil.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Instituto Hermes Pardini SA has the following listings and related stock indices.
Stock: Bovespa: PARD3 wb_incandescent